{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:10:55Z","timestamp":1790745055105,"version":"4.1.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"French National Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gaucher disease (GD) is a rare autosomal recessive lysosomal disorder caused by glucocerebrosidase deficiency, with a prevalence in France of around 1\/130,000 people. The clinical picture of GD is very heterogeneous, ranging from lifelong asymptomatic forms to severe forms with onset during childhood, such as GD type 2 (&lt;\u20091% of cases). GD type 1, the most common form (95% of cases), manifests with varying degrees of organomegaly, cytopenia and bone manifestations. Progressive encephalopathy of varying severity is also observed in GD type 3. Symptoms may result in acute and\/or chronic pain and asthenia, and lead to disability. The aim of the French National Diagnosis and Care Protocol (Protocole National de Diagnostic et de Soins; PNDS) is to provide health care professionals with guidance for the optimal management and care of patients with GD. GD diagnosis is usually based on laboratory analyses revealing low or absent glucocerebrosidase activity, and can be confirmed by identification of glucocerebrosidase (\n                    <jats:italic>GBA1<\/jats:italic>\n                    ) gene pathogenic variants. Additional assessments should include biological analyses (hemogram test, serum protein electrophoresis, and measurement of GD biomarkers), imaging examinations (X-rays, abdominal and bone magnetic resonance imaging, bone densitometry, echocardiography), and electrocardiogram.\n                  <\/jats:p>\n                  <jats:p>Patient management in France is multidisciplinary and should be coordinated by a GD specialist, in conjunction with the Committee for the Evaluation and Treatment of Gaucher Disease, the Reference Center for Lysosomal Diseases or a reference\/competence center for inherited metabolic diseases. The indication for treatment is not systematic and is based on the presence of clinical, biological, and imaging criteria. Current treatments such as intravenous enzyme replacement therapy or oral substrate reduction therapy, generally lead to significant improvements in disease characteristics within one to five years and early initiation can prevent complications. Follow-up should include a clinical examination, biological analyses to monitor disease biomarkers twice a year then yearly for stable patients, and imaging evaluations initially every year and then every 3 to 4\u00a0years for patients with stable disease in whom therapeutic objectives have been achieved. Intercurrent pathologies can be managed by the attending physician in collaboration with a GD specialist.<\/jats:p>","DOI":"10.1186\/s13023-025-03980-1","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:24:18Z","timestamp":1761571458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Fabrice","family":"Camou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Serratrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Pettazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Nadjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Cador-Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Dagneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalbies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Genevaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Guemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Leguy-Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Marcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Masseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves-Marie","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Vergnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-3824","authenticated-orcid":false,"given":"Yann","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"3980_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","volume":"18","author":"RO Brady","year":"1965","unstructured":"Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher\u2019s disease. Biochem Biophys Res Commun. 1965;18:221\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"3980_CR2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","volume":"72","author":"A Tylki-Szymanska","year":"2007","unstructured":"Tylki-Szymanska A, Czartoryska B, Vanier MT, Poorthuis BJ, Groener JA, Lugowska A, et al. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007;72(6):538\u201342.","journal-title":"Clin Genet"},{"key":"3980_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020441","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18020441.","journal-title":"Int J Mol Sci"},{"key":"3980_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77.","journal-title":"Orphanet J Rare Dis"},{"key":"3980_CR5","unstructured":"HAS. (Haute Autorit\u00e9 de Sant\u00e9). Guide methodologique. M\u00e9thode d\u2019\u00e9laboration d\u2019un protocole national de diagnostic et de soins pour les maladies rares. October 2012. Paris: French National Authority for Health. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2012-12\/guide_methodologique_pnds.pdf Accessed 20 Feb 2025."},{"issue":"6","key":"3980_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res. 2019;34(6):996\u20131013.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3980_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13023-016-0435-x","volume":"11","author":"YC Zion","year":"2016","unstructured":"Zion YC, Pappadopulos E, Wajnrajch M, Rosenbaum H. Rethinking fatigue in Gaucher disease. Orphanet J Rare Dis. 2016;11(1):53.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3980_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/08880010290097143","volume":"19","author":"A Dweck","year":"2002","unstructured":"Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D. Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol. 2002;19(6):389\u201397.","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"3980_CR9","first-page":"158","volume":"2","author":"R Kauli","year":"2000","unstructured":"Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy. Isr Med Assoc J. 2000;2(2):158\u201363.","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"3980_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","volume":"46","author":"N Gupta","year":"2011","unstructured":"Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011;46(1):75\u201384.","journal-title":"Blood Cells Mol Dis"},{"issue":"15","key":"3980_CR11","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","volume":"95","author":"T Roshan Lal","year":"2020","unstructured":"Roshan Lal T, Seehra GK, Steward AM, Poffenberger CN, Ryan E, Tayebi N, et al. The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. Neurology. 2020;95(15):e2119\u201330.","journal-title":"Neurology"},{"issue":"4","key":"3980_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","volume":"172","author":"P Kaplan","year":"2013","unstructured":"Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172(4):447\u201358.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"3980_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.0.CO;2-O","volume":"71","author":"CA Prows","year":"1997","unstructured":"Prows CA, Sanchez N, Daugherty C, Grabowski GA. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet. 1997;71(1):16\u201321.","journal-title":"Am J Med Genet"},{"issue":"5","key":"3980_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","volume":"32","author":"A Vellodi","year":"2009","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009;32(5):660\u20134.","journal-title":"J Inherit Metab Dis"},{"issue":"4\u20135","key":"3980_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/15227950500405296","volume":"24","author":"MJ Eblan","year":"2005","unstructured":"Eblan MJ, Goker-Alpan O, Sidransky E. Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum. Fetal Pediatr Pathol. 2005;24(4\u20135):205\u201322.","journal-title":"Fetal Pediatr Pathol"},{"issue":"3","key":"3980_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajmg.a.20117","volume":"120A","author":"C Mignot","year":"2003","unstructured":"Mignot C, Gelot A, Bessieres B, Daffos F, Voyer M, Menez F, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A. 2003;120A(3):338\u201344.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3980_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","volume":"28","author":"C Mignot","year":"2006","unstructured":"Mignot C, Doummar D, Maire I, De Villemeur TB, French Type 2 Gaucher Disease Study G. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28(1):39\u201348.","journal-title":"Brain Dev"},{"issue":"24","key":"3980_CR18","doi-asserted-by":"publisher","first-page":"e2272","DOI":"10.1212\/WNL.0000000000008618","volume":"93","author":"AM Steward","year":"2019","unstructured":"Steward AM, Wiggs E, Lindstrom T, Ukwuani S, Ryan E, Tayebi N, et al. Variation in cognitive function over time in Gaucher disease type 3. Neurology. 2019;93(24):e2272\u201383.","journal-title":"Neurology"},{"issue":"2","key":"3980_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab. 2021;132(2):49\u201358.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3980_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/0218492313513598","volume":"23","author":"G Altunbas","year":"2015","unstructured":"Altunbas G, Ercan S, Inanc IH, Ozer O, Kervancioglu S, Davutoglu V. Extensive vascular and valvular involvement in Gaucher disease. Asian Cardiovasc Thorac Ann. 2015;23(4):446\u20138.","journal-title":"Asian Cardiovasc Thorac Ann"},{"issue":"2","key":"3980_CR21","first-page":"165","volume":"12","author":"L Masi","year":"2015","unstructured":"Masi L, Brandi ML. Gaucher disease: the role of the specialist on metabolic bone diseases. Clin Cases Miner Bone Metab. 2015;12(2):165\u20139.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"6","key":"3980_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.12335","volume":"161","author":"M Arends","year":"2013","unstructured":"Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013;161(6):832\u201342.","journal-title":"Br J Haematol"},{"issue":"1","key":"3980_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","volume":"36","author":"M de Fost","year":"2006","unstructured":"de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36(1):53\u20138.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"3980_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","volume":"18","author":"PK Mistry","year":"2013","unstructured":"Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18(3):235\u201346.","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"3980_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041247","volume":"21","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K, et al. Immunoglobulin abnormalities in Gaucher disease: an analysis of 278 patients included in the French Gaucher Disease Registry. Int J Mol Sci. 2020;21(4): 1247.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3980_CR26","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","volume":"105","author":"BE Rosenbloom","year":"2005","unstructured":"Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105(12):4569\u201372.","journal-title":"Blood"},{"issue":"4","key":"3980_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.21362","volume":"84","author":"TH Taddei","year":"2009","unstructured":"Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84(4):208\u201314.","journal-title":"Am J Hematol"},{"issue":"10","key":"3980_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/archneur.65.10.1353","volume":"65","author":"O Goker-Alpan","year":"2008","unstructured":"Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65(10):1353\u20137.","journal-title":"Arch Neurol"},{"issue":"17","key":"3980_CR29","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"10","key":"3980_CR30","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133(10):2909\u201319.","journal-title":"Brain"},{"issue":"3","key":"3980_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","volume":"31","author":"TM Cox","year":"2008","unstructured":"Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis. 2008;31(3):319\u201336.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3980_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011;90(1):52\u201360.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3980_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/qjmed\/93.4.237","volume":"93","author":"RH Lachmann","year":"2000","unstructured":"Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, et al. Massive hepatic fibrosis in Gaucher\u2019s disease: clinico-pathological and radiological features. QJM. 2000;93(4):237\u201344.","journal-title":"QJM"},{"issue":"5","key":"3980_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","volume":"41","author":"M Regenboog","year":"2018","unstructured":"Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, et al. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018;41(5):819\u201327.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"3980_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","volume":"77","author":"PK Mistry","year":"2002","unstructured":"Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, et al. Pulmonary hypertension in type 1 Gaucher\u2019s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002;77(1\u20132):91\u20138.","journal-title":"Mol Genet Metab"},{"issue":"16","key":"3980_CR36","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118(16):e118\u201327.","journal-title":"Blood"},{"issue":"4","key":"3980_CR37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","volume":"118","author":"S Elliott","year":"2016","unstructured":"Elliott S, Buroker N, Cournoyer JJ, Potier AM, Trometer JD, Elbin C, et al. Pilot study of newborn screening for six lysosomal storage diseases using tandem mass spectrometry. Mol Genet Metab. 2016;118(4):304\u20139.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3980_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215\u201324.","journal-title":"Leukemia"},{"issue":"3","key":"3980_CR39","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","volume":"96","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol. 1997;96(3):470\u20136.","journal-title":"Br J Haematol"},{"issue":"2","key":"3980_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<103::AID-AJH5>3.0.CO;2-V","volume":"61","author":"S Gillis","year":"1999","unstructured":"Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A. Platelet function abnormalities in Gaucher disease patients. Am J Hematol. 1999;61(2):103\u20136.","journal-title":"Am J Hematol"},{"issue":"3","key":"3980_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","volume":"96","author":"P Mikosch","year":"2009","unstructured":"Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet Metab. 2009;96(3):113\u201320.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3980_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","volume":"204","author":"M de Fost","year":"2009","unstructured":"de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JE, de Groot E, et al. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis. 2009;204(1):267\u201372.","journal-title":"Atherosclerosis"},{"key":"3980_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197159","author":"S Revel-Vilk","year":"2020","unstructured":"Revel-Vilk S, Fuller M, Zimran A. Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21197159.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3980_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079732","volume":"8","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE. 2013;8(11): e79732.","journal-title":"PLoS ONE"},{"issue":"11","key":"3980_CR45","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91(11):1082\u20139.","journal-title":"Am J Hematol"},{"key":"3980_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123033","author":"N Hurvitz","year":"2019","unstructured":"Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, et al. Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20123033.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3980_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181700","volume":"12","author":"M Pettazzoni","year":"2017","unstructured":"Pettazzoni M, Froissart R, Pagan C, Vanier MT, Ruet S, Latour P, et al. LC-MS\/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease. PLoS ONE. 2017;12(7): e0181700.","journal-title":"PLoS ONE"},{"issue":"3","key":"3980_CR48","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93(3):1288\u201392.","journal-title":"J Clin Invest"},{"issue":"40","key":"3980_CR49","doi-asserted-by":"publisher","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680\u20135.","journal-title":"J Biol Chem"},{"issue":"1","key":"3980_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103(1):33\u20139.","journal-title":"Blood"},{"issue":"2","key":"3980_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2013initial experience. Radiology. 2003;229(2):554\u201361.","journal-title":"Radiology"},{"key":"3980_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134577","author":"C Cozma","year":"2020","unstructured":"Cozma C, Cullufi P, Kramp G, Hovakimyan M, Velmishi V, Gjikopulli A, et al. Treatment efficiency in Gaucher patients can reliably be monitored by quantification of lyso-Gb1 concentrations in dried blood spots. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21134577.","journal-title":"Int J Mol Sci"},{"key":"3980_CR53","unstructured":"EMA. (European Medicine Agency). Cerezyme 400. Summary of product characteristics for imiglucerase. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerezyme-epar-product-information_en.pdf Accessed 20 Feb 2025."},{"key":"3980_CR54","unstructured":"EMA. (European Medicine Agency). VPRIV 400. Summary of product characteristics for veraglucerase alfa. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vpriv-epar-product-information_en.pdf Accessed 20 Feb 2025."},{"key":"3980_CR55","unstructured":"EMA. (European Medicine Agency). ZAVESCA. Summary of product characteristics for miglustat. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavesca-epar-product-information_en.pdf Accessed 20 Feb 2025."},{"key":"3980_CR56","unstructured":"EMA. (European Medicine Agency). CERDELGA. Summary of product characteristics for eliglustat. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerdelga-epar-product-information_en.pdf Accessed 20 Feb 2025."},{"issue":"2","key":"3980_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS Jr., Charrow J, McClain MR, Mistry P, Belmatoug N. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132(2):100\u201311.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"3980_CR58","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris Feldman H, Ghosn M, et al. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156\u201365.","journal-title":"Am J Hematol"},{"key":"3980_CR59","first-page":"CD010324","volume":"3","author":"E Shemesh","year":"2015","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015;3:CD010324.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"3980_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706.","journal-title":"JAMA"},{"issue":"4","key":"3980_CR61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"GM Pastores","year":"2014","unstructured":"Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53(4):253\u201360.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"3980_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.23381","volume":"88","author":"DE Gonzalez","year":"2013","unstructured":"Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013;88(3):166\u201371.","journal-title":"Am J Hematol"},{"issue":"3","key":"3980_CR63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.23382","volume":"88","author":"H Ben Turkia","year":"2013","unstructured":"Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88(3):179\u201384.","journal-title":"Am J Hematol"},{"issue":"1","key":"3980_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33\u20139.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3980_CR65","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110(7):2296\u2013301.","journal-title":"Blood"},{"key":"3980_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bcmd.2016.10.014","volume":"68","author":"P Deegan","year":"2018","unstructured":"Deegan P, Fernandez-Sasso D, Giraldo P, Lau H, Panahloo Z, Zimran A. Treatment patterns from 647 patients with Gaucher disease: an analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:218\u201325.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"3980_CR67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","volume":"123","author":"J Charrow","year":"2018","unstructured":"Charrow J, Fraga C, Gu X, Ida H, Longo N, Lukina E, et al. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial. Mol Genet Metab. 2018;123(3):347\u201356.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"3980_CR68","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.24012","volume":"90","author":"DA Hughes","year":"2015","unstructured":"Hughes DA, Gonzalez DE, Lukina EA, Mehta A, Kabra M, Elstein D, et al. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. Am J Hematol. 2015;90(7):584\u201391.","journal-title":"Am J Hematol"},{"issue":"17","key":"3980_CR69","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","volume":"129","author":"TM Cox","year":"2017","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375\u201383.","journal-title":"Blood"},{"issue":"9985","key":"3980_CR70","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355\u201362.","journal-title":"Lancet"},{"issue":"2","key":"3980_CR71","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","volume":"51","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013;51(2):116\u201324.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"3980_CR72","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10245330500067181","volume":"10","author":"A Zimran","year":"2005","unstructured":"Zimran A, Altarescu G, Rudensky B, Abrahamov A, Elstein D. Survey of hematological aspects of Gaucher disease. Hematology. 2005;10(2):151\u20136.","journal-title":"Hematology"},{"issue":"6","key":"3980_CR73","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","volume":"138","author":"D Hughes","year":"2007","unstructured":"Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol. 2007;138(6):676\u201386.","journal-title":"Br J Haematol"},{"issue":"4 Suppl 5","key":"3980_CR74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl 5):4\u201314.","journal-title":"Semin Hematol"},{"issue":"5","key":"3980_CR75","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73(5):430\u201340.","journal-title":"Clin Genet"},{"issue":"1","key":"3980_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22(1):119\u201326.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"3980_CR77","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","volume":"28","author":"G Ciana","year":"2005","unstructured":"Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005;28(5):723\u201332.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3980_CR78","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00774-004-0529-8","volume":"22","author":"E Lebel","year":"2004","unstructured":"Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab. 2004;22(6):597\u2013601.","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"3980_CR79","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00330-015-3715-2","volume":"25","author":"B Fedida","year":"2015","unstructured":"Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo JD, Petrover D. Bone marrow involvement in Gaucher disease at MRI\u202f: what long-term evolution can we expect under enzyme replacement therapy? Eur Radiol. 2015;25(10):2969\u201375.","journal-title":"Eur Radiol"},{"issue":"2","key":"3980_CR80","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","volume":"33","author":"I Kraoua","year":"2011","unstructured":"Kraoua I, Sedel F, Caillaud C, Froissart R, Stirnemann J, Chaurand G, et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev. 2011;33(2):131\u20139.","journal-title":"Brain Dev"},{"issue":"6","key":"3980_CR81","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10545-007-0577-z","volume":"30","author":"EH Davies","year":"2007","unstructured":"Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis. 2007;30(6):935\u201342.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"3980_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab. 2017;120(1\u20132):47\u201356.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3980_CR83","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1067\/mpd.2001.112171","volume":"138","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease. J Pediatr. 2001;138(4):539\u201347.","journal-title":"J Pediatr"},{"issue":"1","key":"3980_CR84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s004310000630","volume":"160","author":"M Aoki","year":"2001","unstructured":"Aoki M, Takahashi Y, Miwa Y, Iida S, Sukegawa K, Horai T, et al. Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb. Eur J Pediatr. 2001;160(1):63\u20134.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"3980_CR85","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1002\/ajh.25074","volume":"93","author":"D Arkadir","year":"2018","unstructured":"Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, et al. Glucosylsphingosine is a reliable response biomarker in Gaucher disease. Am J Hematol. 2018;93(6):E140\u20132.","journal-title":"Am J Hematol"},{"issue":"2","key":"3980_CR86","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","volume":"35","author":"PB Deegan","year":"2005","unstructured":"Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35(2):259\u201367.","journal-title":"Blood Cells Mol Dis"},{"key":"3980_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016;11:28.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3980_CR88","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","volume":"158","author":"CE Hollak","year":"2012","unstructured":"Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, et al. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135 years. Br J Haematol. 2012;158(4):528\u201338.","journal-title":"Br J Haematol"},{"key":"3980_CR89","unstructured":"HCSP. (French High Council for Public Health). Vaccination of immunocompromised or asplenic persons. Updated recommendations. France: Haut Conseil de la Sant\u00e9 Publique; 2014 Nov 07. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=504 Accessed 20 Feb 2025."},{"issue":"3","key":"3980_CR90","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.arcped.2011.12.015","volume":"19","author":"M Vidailhet","year":"2012","unstructured":"Vidailhet M, Mallet E, Bocquet A, Bresson JL, Briend A, Chouraqui JP, et al. Vitamin D: still a topical matter in children and adolescents. A position paper by the Committee on Nutrition of the French Society of Paediatrics. Arch Pediatr. 2012;19(3):316\u201328.","journal-title":"Arch Pediatr"},{"key":"3980_CR91","unstructured":"Direction\u00a0g\u00e9n\u00e9rale\u00a0de\u00a0la\u00a0sant\u00e9\u00a0et\u00a0de\u00a0l\u2019acc\u00e8s\u00a0aux\u00a0soins. Calendrier des vaccinations et recommandations vaccinales 2024. Paris: Minist\u00e8re de la Sant\u00e9 et de l'Acc\u00e8s aux soins; 2024 Dec [cited 2025 Feb 20]. Available from: https:\/\/sante.gouv.fr\/IMG\/pdf\/calendrier_vaccinal_dec24.pdf. 2024."},{"key":"3980_CR92","unstructured":"SFAR. Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation. Antibioprophylaxy in surgery and interventional medicine (adult patients). 2018 update. France: Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation; 21 Jun 2018. https:\/\/sfar.org\/wp-content\/uploads\/2018\/07\/Antibioprophylaxie-RFE-mise-a-jour-2018.pdf Accessed 20 Feb 2025. 2018."},{"issue":"5","key":"3980_CR93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1601-0825.2011.01898.x","volume":"18","author":"HR Saranjam","year":"2012","unstructured":"Saranjam HR, Sidransky E, Levine WZ, Zimran A, Elstein D. Mandibular and dental manifestations of Gaucher disease. Oral Dis. 2012;18(5):421\u20139.","journal-title":"Oral Dis"},{"key":"3980_CR94","volume":"25","author":"G Ciana","year":"2020","unstructured":"Ciana G, Dardis A, Pavan E, Da Riol RM, Biasizzo J, Ferino D, et al. In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy. Mol Genet Metab Rep. 2020;25: 100678.","journal-title":"Mol Genet Metab Rep"},{"key":"3980_CR95","doi-asserted-by":"crossref","unstructured":"Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's disease. 2021.","DOI":"10.3233\/JPD-212714"},{"issue":"6","key":"3980_CR96","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/mt.2016.53","volume":"24","author":"J Marshall","year":"2016","unstructured":"Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, et al. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther. 2016;24(6):1019\u201329.","journal-title":"Mol Ther"},{"key":"3980_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102735","volume":"55","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liou B, Chu Z, Fannin V, Blackwood R, Peng Y, et al. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020;55: 102735.","journal-title":"EBioMedicine"},{"issue":"3","key":"3980_CR98","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1021\/acs.jmedchem.8b01294","volume":"62","author":"J Zheng","year":"2019","unstructured":"Zheng J, Jeon S, Jiang W, Burbulla LF, Ysselstein D, Oevel K, et al. Conversion of quinazoline modulators from inhibitors to activators of beta-glucocerebrosidase. J Med Chem. 2019;62(3):1218\u201330.","journal-title":"J Med Chem"},{"issue":"17","key":"3980_CR99","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","volume":"9","author":"CE Dunbar","year":"1998","unstructured":"Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther. 1998;9(17):2629\u201340.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"3980_CR100","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/mt.2015.16","volume":"23","author":"M Dahl","year":"2015","unstructured":"Dahl M, Doyle A, Olsson K, Mansson JE, Marques ARA, Mirzaian M, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther. 2015;23(5):835\u201344.","journal-title":"Mol Ther"},{"issue":"5","key":"3980_CR101","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/jimd.12382","volume":"44","author":"Y Cohen","year":"2021","unstructured":"Cohen Y, Frydman D, Rotem R, Kofman R, Zimran A, Revel-Vilk S, et al. Risk of postpartum hemorrhage in multiparous women with Gaucher disease: a call for reconsidering enzyme replacement therapy in all pregnant patients. J Inherit Metab Dis. 2021;44(5):1165\u201373.","journal-title":"J Inherit Metab Dis"},{"key":"3980_CR102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejogrb.2020.09.027","volume":"254","author":"V Komninaka","year":"2020","unstructured":"Komninaka V, Flevari P, Marinakis T, Karkaletsis G, Malakou L, Repa K. Outcomes of pregnancies in patients with Gaucher Disease: the experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece. Eur J Obstet Gynecol Reprod Biol. 2020;254:181\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"3980_CR103","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/jog.12254","volume":"40","author":"D Elstein","year":"2014","unstructured":"Elstein D, Hughes D, Goker-Alpan O, Stivel M, Baris HN, Cohen IJ, et al. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res. 2014;40(4):968\u201375.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"3980_CR104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejogrb.2010.12.024","volume":"156","author":"S Granovsky-Grisaru","year":"2011","unstructured":"Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156(1):3\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"3980_CR105","first-page":"76","volume":"57","author":"E Lukina","year":"2021","unstructured":"Lukina E, Balwani M, Belmatoug N, Watman N, Hughes D, Gaemers SJM, et al. Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials. JIMD Rep. 2021;57(1):76\u201384.","journal-title":"JIMD Rep"},{"issue":"4","key":"3980_CR106","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bjh.12804","volume":"165","author":"AS Thomas","year":"2014","unstructured":"Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165(4):427\u201340.","journal-title":"Br J Haematol"},{"issue":"2","key":"3980_CR107","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.beem.2014.08.007","volume":"29","author":"D Elstein","year":"2015","unstructured":"Elstein D, Alcalay R, Zimran A. The emergence of Parkinson disease among patients with Gaucher disease. Best Pract Res Clin Endocrinol Metab. 2015;29(2):249\u201359.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"3980_CR108","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752\u20137.","journal-title":"JAMA Neurol"},{"issue":"2","key":"3980_CR109","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson\u2019s disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33(2):167\u201373.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3980_CR110","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S Vom Dahl","year":"2006","unstructured":"Vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin. 2006;22(6):1045\u201364.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"3980_CR111","first-page":"S19","volume":"90","author":"J Charrow","year":"2015","unstructured":"Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015;90(Suppl 1):S19-24.","journal-title":"Am J Hematol"},{"issue":"4 Suppl 5","key":"3980_CR112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(4 Suppl 5):15\u201322.","journal-title":"Semin Hematol"},{"issue":"1","key":"3980_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1005655031239","volume":"23","author":"P Maaswinkel-Mooij","year":"2000","unstructured":"Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, Poll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis. 2000;23(1):77\u201382.","journal-title":"J Inherit Metab Dis"},{"key":"3980_CR114","unstructured":"CETL. (Comit\u00e9 d'Evaluation du Traitement des maladies Lysosomales). Committee for the Evaluation and Treatment of Lysosomal Diseases. Patient consent form. https:\/\/www.cetl.net\/maladies-lysosomales\/cetg-maladie-de-gaucher\/registre-46\/ Accessed 20 Feb 2025."},{"issue":"1","key":"3980_CR115","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-022-02232-w","volume":"17","author":"D Genevaz","year":"2022","unstructured":"Genevaz D, Arnoux A, Marcel C, Brassier A, Pichard S, Feillet F, et al. Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey. Orphanet J Rare Dis. 2022;17(1):68.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3980_CR116","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/ar3111","volume":"12","author":"J Stirnemann","year":"2010","unstructured":"Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther. 2010;12(4):R156.","journal-title":"Arthritis Res Ther"},{"key":"3980_CR117","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13023-015-0275-0","volume":"10","author":"J Stirnemann","year":"2015","unstructured":"Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, et al. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1. Orphanet J Rare Dis. 2015;10:62.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3980_CR118","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ajh.24040","volume":"90","author":"A Zimran","year":"2015","unstructured":"Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D. Seven-year safety and efficacy with velaglucerase alfa for treatment-naive adult patients with type 1 Gaucher disease. Am J Hematol. 2015;90(7):577\u201383.","journal-title":"Am J Hematol"},{"issue":"3","key":"3980_CR119","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543\u201353.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3980_CR120","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40262-018-0708-8","volume":"58","author":"J Berger","year":"2019","unstructured":"Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, et al. Intra-monocyte pharmacokinetics of imiglucerase supports a possible personalized management of Gaucher disease type 1. Clin Pharmacokinet. 2019;58(4):469\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3980_CR121","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.ejim.2011.11.017","volume":"23","author":"C Serratrice","year":"2012","unstructured":"Serratrice C, Swiader L, Serratrice J, Weiller PJ, Verrot D. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease. Eur J Intern Med. 2012;23(2):e71\u20132.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"3980_CR122","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3324\/haematol.10635","volume":"92","author":"M de Fost","year":"2007","unstructured":"de Fost M, Aerts JM, Groener JE, Maas M, Akkerman EM, Wiersma MG, et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica. 2007;92(2):215\u201321.","journal-title":"Haematologica"},{"key":"3980_CR123","doi-asserted-by":"crossref","unstructured":"Hollak CE, de Fost M, Aerts JM, vom Dahl S. Low-dose versus high-dose therapy for Gaucher disease: Goals and markers. Blood. 2007;109(1):387; author reply -8.","DOI":"10.1182\/blood-2006-07-033233"},{"issue":"4","key":"3980_CR124","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","volume":"96","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab. 2009;96(4):164\u201370.","journal-title":"Mol Genet Metab"},{"key":"3980_CR125","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","volume":"59","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AA, Qin Y, et al. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease. Blood Cells Mol Dis. 2016;59:37\u201343.","journal-title":"Blood Cells Mol Dis"},{"issue":"1\u20132","key":"3980_CR126","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jim.2011.07.020","volume":"373","author":"M Sellos-Moura","year":"2011","unstructured":"Sellos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, et al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods. 2011;373(1\u20132):45\u201353.","journal-title":"J Immunol Methods"},{"issue":"1","key":"3980_CR127","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1079-9796(03)00012-3","volume":"30","author":"H Zhao","year":"2003","unstructured":"Zhao H, Bailey LA, Grabowski GA. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis. 2003;30(1):90\u20136.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"3980_CR128","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","volume":"33","author":"TH Taddei","year":"2010","unstructured":"Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, et al. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis. 2010;33(3):291\u2013300.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3980_CR129","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2459\/JCM.0000000000000326","volume":"18","author":"A Roghi","year":"2017","unstructured":"Roghi A, Poggiali E, Cassinerio E, Pedrotti P, Giuditta M, Milazzo A, et al. The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients: morphological and functional evaluations. J Cardiovasc Med (Hagerstown). 2017;18(4):244\u20138.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"3","key":"3980_CR130","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.1984.tb04731.x","volume":"111","author":"J Goldblatt","year":"1984","unstructured":"Goldblatt J, Beighton P. Cutaneous manifestations of Gaucher disease. Br J Dermatol. 1984;111(3):331\u20134.","journal-title":"Br J Dermatol"},{"key":"3980_CR131","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bcmd.2016.09.002","volume":"68","author":"M Kocic","year":"2018","unstructured":"Kocic M, Djuricic SM, Djordjevic M, Savic D, Kecman B, Sarajlija A. Appendiceal involvement in a patient with Gaucher disease. Blood Cells Mol Dis. 2018;68:109\u201311.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"3980_CR132","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1159\/000354725","volume":"7","author":"J Ito","year":"2013","unstructured":"Ito J, Saito T, Numakura C, Iwaba A, Sugahara S, Ishii R, et al. A case of adult type 1 Gaucher disease complicated by temporal intestinal hemorrhage. Case Rep Gastroenterol. 2013;7(2):340\u20136.","journal-title":"Case Rep Gastroenterol"},{"issue":"787","key":"3980_CR133","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/pgmj.67.787.479","volume":"67","author":"DR Jones","year":"1991","unstructured":"Jones DR, Hoffman J, Downie R, Haqqani M. Massive gastrointestinal haemorrhage associated with ileal lymphoid hyperplasia in Gaucher\u2019s disease. Postgrad Med J. 1991;67(787):479\u201381.","journal-title":"Postgrad Med J"},{"issue":"3","key":"3980_CR134","first-page":"346","volume":"86","author":"JM Henderson","year":"1991","unstructured":"Henderson JM, Gilinsky NH, Lee EY, Greenwood MF. Gaucher\u2019s disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells. Am J Gastroenterol. 1991;86(3):346\u20138.","journal-title":"Am J Gastroenterol"},{"key":"3980_CR135","volume":"22","author":"RT Starosta","year":"2020","unstructured":"Starosta RT, Vairo FPE, Dornelles AD, Basgalupp SP, Siebert M, Pedroso MLA, et al. Liver involvement in patients with Gaucher disease types I and III. Mol Genet Metab Rep. 2020;22: 100564.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"3980_CR136","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13023-019-1211-5","volume":"14","author":"M Kaluzna","year":"2019","unstructured":"Kaluzna M, Trzeciak I, Ziemnicka K, Machaczka M, Ruchala M. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis. 2019;14(1):275.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3980_CR137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ymgme.2019.02.002","volume":"127","author":"A Eghbali","year":"2019","unstructured":"Eghbali A, Hassan S, Seehra G, FitzGibbon E, Sidransky E. Ophthalmological findings in Gaucher disease. Mol Genet Metab. 2019;127(1):23\u20137.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3980_CR138","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.ajkd.2005.07.042","volume":"46","author":"R Becker-Cohen","year":"2005","unstructured":"Becker-Cohen R, Elstein D, Abrahamov A, Algur N, Rudensky B, Hadas-Halpern I, et al. A comprehensive assessment of renal function in patients with Gaucher disease. Am J Kidney Dis. 2005;46(5):837\u201344.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3980_CR139","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/qjmed\/hcg006","volume":"96","author":"B Dayan","year":"2003","unstructured":"Dayan B, Elstein D, Zimran A, Nesher G. Decreased salivary output in patients with Gaucher disease. QJM. 2003;96(1):53\u20136.","journal-title":"QJM"},{"issue":"12","key":"3980_CR140","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.revmed.2019.07.011","volume":"40","author":"S Deriaz","year":"2019","unstructured":"Deriaz S, Serratrice C, Lidove O, Noel E, Masseau A, Lorcerie B, et al. Parcours diagnostique des patients atteints de maladie de Gaucher de type 1\u00a0: enqu\u00eate aupr\u00e8s de m\u00e9decins internistes et h\u00e9matologues. Rev Med Interne. 2019;40(12):778\u201384.","journal-title":"Rev Med Interne"},{"issue":"8","key":"3980_CR141","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697\u2013701.","journal-title":"Am J Hematol"},{"issue":"1","key":"3980_CR142","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","volume":"86","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110\u20135.","journal-title":"Am J Hematol"},{"issue":"3","key":"3980_CR143","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","volume":"122","author":"A Mehta","year":"2017","unstructured":"Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Goker-Alpan O, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122(3):122\u20139.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3980_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82296-z","volume":"11","author":"I Motta","year":"2021","unstructured":"Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, et al. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Sci Rep. 2021;11(1): 2594.","journal-title":"Sci Rep"},{"key":"3980_CR145","unstructured":"HAS. (Haute Autorit\u00e9 de Sant\u00e9). French National Health Authority. https:\/\/www.has-sante.fr\/ Accessed 20 Feb 2025."},{"key":"3980_CR146","unstructured":"CETL. (Comit\u00e9 d'Evaluation du Traitement des maladies Lysosomales). Committee for the Evaluation and Treatment of Lysosomal Diseases. https:\/\/www.cetl.net\/ Accessed 20 Feb 2025."},{"key":"3980_CR147","unstructured":"ORPHANET. https:\/\/www.orpha.net\/#menu Accessed 20 Feb 2025."},{"key":"3980_CR148","unstructured":"VLM. (Vaincre les Maladies lysosomales). French Patient Association for Lysosomal Diseases. https:\/\/www.vml-asso.org\/ Accessed 20 Feb 2025."},{"key":"3980_CR149","unstructured":"G2M. (Reseau des maladies rares h\u00e9r\u00e9ditaires du m\u00e9tabolisme). Protocoles d\u2019urgence et cartes urgence. Emergency information sheets and emergency cards. https:\/\/www.filiere-g2m.fr\/urgences Accessed 20 Feb 2025."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03980-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03980-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03980-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:04:15Z","timestamp":1761573855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03980-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03980-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"As experts in GD, most members of the CETG have links with the pharmaceutical industry (invitations to conferences, interventions as speakers, project grants, etc.). However, none of the members has an exclusive relationship with any one industrial body. No members of the pharmaceutical industry were involved in drafting or reviewing the PNDS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}